{"id":"NCT01675661","sponsor":"Medical University of South Carolina","briefTitle":"Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment","officialTitle":"Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2015-07","completion":"2015-08","firstPosted":"2012-08-30","resultsPosted":"2017-03-08","lastUpdate":"2018-05-24"},"enrollment":302,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cannabis Dependence"],"interventions":[{"type":"DRUG","name":"N-Acetylcysteine","otherNames":["NAC"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"NAC plus CM","type":"ACTIVE_COMPARATOR"},{"label":"Placebo plus CM","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).","primaryOutcome":{"measure":"The Odds of Negative Urine Cannabinoid Tests During Treatment.","timeFrame":"study weeks 2-13","effectByArm":[{"arm":"NAC Plus CM","deltaMin":25,"sd":null},{"arm":"Placebo Plus CM","deltaMin":21,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.985"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["25179587","35084903","34197135","31712969","28847455","28623823"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["Headache","Nausea","Diarrhea","Abdominal discomfort","Dyspepsia"]}}